Avid Bioservices, Inc. (CDMO)
NASDAQ: CDMO · IEX Real-Time Price · USD
9.22
+0.10 (1.10%)
May 20, 2024, 9:56 AM EDT - Market open

Company Description

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries.

The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support.

It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization.

The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.

Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Avid Bioservices, Inc.
Avid Bioservices logo
Country United States
Founded 1981
Industry Biotechnology
Sector Healthcare
Employees 365
CEO Nicholas Stewart Green B.Sc., MBA

Contact Details

Address:
14191 Myford Road
Tustin, California 92780
United States
Phone 714.508.6100
Website avidbio.com

Stock Details

Ticker Symbol CDMO
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency USD
CIK Code 0000704562
CUSIP Number 05368M106
ISIN Number US05368M1062
Employer ID 95-3698422
SIC Code 2834

Key Executives

Name Position
Nicholas Stewart Green B.Sc., MBA President, Chief Executive Officer and Director
Daniel R. Hart Chief Financial Officer
Richard Richieri Chief Operations Officer
Mark R. Ziebell J.D. Vice President, General Counsel and Corporate Secretary
Matthew Kwietniak Chief Commercial Officer
Oksana Lukash Vice President of People

Latest SEC Filings

Date Type Title
Apr 30, 2024 144 Filing
Apr 26, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Apr 25, 2024 8-K Current Report
Apr 24, 2024 10-Q Quarterly Report
Apr 24, 2024 10-Q/A [Amend] Quarterly report
Apr 24, 2024 10-Q/A [Amend] Quarterly report
Apr 24, 2024 10-K/A [Amend] Annual report
Apr 17, 2024 SCHEDULE 13G Filing
Mar 20, 2024 8-K Current Report
Mar 14, 2024 8-K Current Report